|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/00 |
| (11) | Number of the document | 2134330 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08744091.3 |
| Date of filing the European patent application | 2008-03-19 | |
| (97) | Date of publication of the European application | 2009-12-23 |
| (45) | Date of publication and mention of the grant of the patent | 2013-05-08 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2008/057557 |
| Date | 2008-03-19 |
| (87) | Number | WO 2008/116024 |
| Date | 2008-09-25 |
| (30) | Number | Date | Country code |
| 895735 P | 2007-03-19 | US | |
| 908921 P | 2007-03-29 | US | |
| 12771 | 2007-12-10 | US | |
| 26092 | 2008-02-04 | US |
| (72) |
PETERS, Perry, US
FURLANO, David, US
BAHR, Daun, US
VAN KAMMEN, Daniel, US
BRANN, Mark, US
|
| (73) |
Acadia Pharmaceuticals Inc.,
3911 Sorrento Valley Blvd., San Diego, CA 92121-1402,
US
|
| (54) | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS |
| COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS |